efinopegdutide vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
efinopegdutide
Developed by Merck & Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06309992 · Phase 3 · completed
This phase 3 trial randomly assigned 216 adults with obesity and at-risk MASLD (2:1) to weekly survodutide 6.0 mg or placebo, with double-blind treatment for 48 weeks. The first co-primary endpoint was a reduction of at least 30% in liver fat on MRI: 84.2% of survodutide patients reached it against 24.3% on placebo (P<0.0001). The second co-primary endpoint was body weight change: -12.2% against -1.0% (P<0.0001). Both co-primary endpoints were met, so the result is met. The figures come from the peer-reviewed Nature Medicine paper.
Next expected readout: April 2029 · NCT07850063 (registry estimate)
Reported efficacy
Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] (at baseline, at week 48); Relative change (%) in body weight [kg] from baseline to Week 48 (at baseline, at week 48): Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. (met)
Result source: NCT06309992
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | efinopegdutide | survodutide |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | —Not posted · NCT06309992 |
| Fibrosis stage, change | —Not reported | —Not posted · NCT06309992 |
| Liver fat (MRI-PDFF), change | —Not reported | -13.0% vs -1.9%−11.1 vs placeboNCT0477127311 other results
|
| ALT, change | —Not reported | —Not posted · NCT06309992 |
MASH resolution without fibrosis worsening
- efinopegdutide
- —Not reported
- survodutide
- —Not posted · NCT06309992
Fibrosis stage, change
- efinopegdutide
- —Not reported
- survodutide
- —Not posted · NCT06309992
Liver fat (MRI-PDFF), change
- efinopegdutide
- —Not reported
- survodutide
- -13.0% vs -1.9%−11.1 vs placeboNCT04771273
11 other results
- -12.5% vs -1.6% NCT04771273
- -64.3% vs -7.3% NCT04771273
- -62.0% vs -5.7% NCT04771273
- -12.8% vs -1.9% NCT04771273
- -12.4% vs -1.6% NCT04771273
- -62.8% vs -7.3% NCT04771273
- -60.8% vs -5.7% NCT04771273
- -10.5% vs -1.9% NCT04771273
- -10.7% vs -1.6% NCT04771273
- -50.9% vs -7.3% NCT04771273
- -52.2% vs -5.7% NCT04771273
ALT, change
- efinopegdutide
- —Not reported
- survodutide
- —Not posted · NCT06309992
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
efinopegdutide: no structured comparison results are available for MASH / NASH.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. efinopegdutide: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | survodutide |
|---|---|
| Dropout rate | —6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results24%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 13.7%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 15.1%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results16%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 12.3%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 11%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 9.6%6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results—6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence 10.1%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 5.4%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 6.0 mga nausea 63.5% (placebo 27.8%) diarrhoea 55.8% (placebo 25.3%) constipation 28.8% (placebo 17.7%) NCT04771273 · Phase 2 · registry result, not featured evidence show 2 more results4.8 mg nausea 66.7% (placebo 27.8%) diarrhoea 53.6% (placebo 25.3%) vomiting 47.8% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 64.5% (placebo 27.8%) diarrhoea 40.9% (placebo 25.3%) vomiting 40.9% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
survodutide
show 5 more results
show 5 more results
show 11 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efinopegdutide's landscape · survodutide's landscape